参考文献/References:
[1].Li T,Chen Y,Gua C,et al. Elevated circulating trimethylamine N-oxide levels contribute to endothelial dysfunction in aged rats through vascular inflammation and oxidative stress[J]. Front Physiol,2017,8:350.
[2].Collot-Teixeira S,Martin J,McDermott-Roe C,et al. CD36 and macrophages in atherosclerosis[J]. Cardiovasc Res,2007,75(3):468-477.
[3].Yu XH,Fu YC,Zhang DW,et al. Foam cells in atherosclerosis[J]. Clin Chim Acta,2013,424:245-252.
[4].Boullier A,Bird DA,Chang MK,et al. Scavenger receptors,oxidized LDL,and atherosclerosis[J]. Ann N Y Acad Sci,2001,947:214-222.
[5].Mohammadi A,Najar AG,Yaghoobi MM,et al. Trimethylamine-N-oxide treatment induces changes in the ATP-binding cassette transporter A1 and scavenger receptor A1 in murine macrophage J774A.1 cells[J]. Inflammation,2016,39(1):393-404.
[6].Zhu Y,Li Q,Jiang H. Gut microbiota in atherosclerosis:focus on trimethylamine N-oxide[J]. APMIS,2020,128(5):353-366.
[7].Zhu W,Wang Z,Tang WHW,et al. Gut microbe-generated trimethylamine N-oxide from dietary choline is prothrombotic in subjects[J]. Circulation,2017,135(17):1671-1673.
[8].Zhu W,Gregory JC,Org E,et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk[J]. Cell,2016,165(1):111-124.
[9].Huang PH,Chen JW,Lin SJ. Effects of cardiovascular risk factors on endothelial progenitor cell[J]. Acta Cardiol Sin,2014,30(5):375-381.
[10].Vasa M,Fichtlscherer S,Aicher A,et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease[J]. Circ Res,2001,89(1):E1-E7.
[11].Chou RH,Chen CY,Chen IC,et al. Trimethylamine N-oxide,circulating endothelial progenitor cells,and endothelial function in patients with stable angina[J]. Sci Rep,2019,9(1):4249.
[12].Deanfield JE,Halcox JP,Rabelink TJ. Endothelial function and dysfunction:testing and clinical relevance[J]. Circulation,2007,115(10):1285-1295.
[13].Dokusova OK. Conversion of cholesterol into bile acids and regulation of this process[J]. Vopr Med Khim,1975,21(5):461-469.
[14].Lefebvre P,Cariou B,Lien F,et al. Role of bile acids and bile acid receptors in metabolic regulation[J]. Physiol Rev,2009,89(1):147-191.
[15].Sinal CJ,Tohkin M,Miyata M,et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis[J]. Cell,2000,102(6):731-744.
[16].Ding L,Chang M,Guo Y,et al. Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism[J]. Lipids Health Dis,2018,17(1):286.
[17].Seldin MM,Meng Y,Qi H,et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB[J]. J Am Heart Assoc,2016,5(2):e002767.
[18].Chen ML,Yi L,Zhang Y,et al. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota[J]. mBio,2016,7(2):e02210- e02215.
[19].Sun X,Jiao X,Ma Y,et al. Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome[J]. Biochem Biophys Res Commun,2016,481(1-2):63-70.
[20].Janoudi A,Shamoun FE,Kalavakunta JK,et al. Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque[J]. Eur Heart J,2016,37(25):1959-1967.
[21].Cheng X,Qiu X,Liu Y,et al. Trimethylamine N-oxide promotes tissue factor expression and activity in vascular endothelial cells:a new link between trimethylamine N-oxide and atherosclerotic thrombosis[J]. Thromb Res,2019,177:110-116.
[22].Waleed KB,Tse G,Lu YK,et al. Trimethylamine N-oxide is associated with coronary atherosclerotic burden in non-ST-segment myocardial infarction patients:SZ-NSTEMI prospective cohort study[J]. Rev Cardiovasc Med,2021,22(1):231-238.
[23].Senthong V,Li XS,Hudec T,et al. Plasma trimethylamine N-oxide,a gut microbe-generated phosphatidylcholine metabolite,is associated with atherosclerotic burden[J]. J Am Coll Cardiol,2016,67(22):2620-2628.
[24].Sheng Z,Tan Y,Liu C,et al. Relation of circulating trimethylamine N-oxide with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction[J]. Am J Cardiol,2019,123(6):894-898.
[25].Li J,Sheng Z,Tan Y,et al. Association of plasma trimethylamine N-oxide level with healed culprit plaques examined by optical coherence tomography in patients with ST-segment elevation myocardial infarction[J]. Nutr Metab Cardiovasc Dis,2021,31(1):145-152.
[26].Liu X,Xie Z,Sun M,et al. Plasma trimethylamine N-oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography[J]. Int J Cardiol,2018,265:18-23.
[27].M?ller B,Hippe H,Gottschalk G. Degradation of various amine compounds by mesophilic clostridia[J]. Arch Microbiol,1986,145(1):85-90.
[28].Zhu Y,Jameson E,Crosatti M,et al. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota[J]. Proc Natl Acad Sci U S A,2014,111(11):4268-4273.
[29].Qiu L,Yang D,Tao X,et al. Enterobacter aerogenes ZDY01 attenuates choline-induced trimethylamine N-oxide levels by remodeling gut microbiota in mice[J]. J Microbiol Biotechnol,2017,27(8):1491-1499.
[30].Wang Z,Roberts AB,Buffa JA,et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis[J]. Cell,2015,163(7):1585-1595.
[31].Ramezani A,Nolin TD,Barrows IR,et al. Gut Colonization with methanogenic archaea lowers plasma trimethylamine N-oxide concentrations in apolipoprotein e-/- mice[J]. Sci Rep,2018,8(1):14752.
[32].Feng X,Sureda A,Jafari S,et al. Berberine in cardiovascular and metabolic diseases:from mechanisms to therapeutics[J]. Theranostics,2019,9(7):1923-1951.
[33].Li X,Su C,Jiang Z,et al. Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome[J]. NPJ Biofilms Microbiomes,2021,7(1):36.
[34].Annunziata G,Maisto M,Schisano C,et al. Effects of grape pomace polyphenolic extract (Taurisolo?) in reducing TMAO serum levels in humans:preliminary results from a randomized,placebo-controlled,cross-over study[J]. Nutrients,2019,11(1):139.
[35].Wu WK,Panyod S,Ho CT,et al. Dietary allicin reduces transformation of L-carnitine to TMAO through impact on gut microbiota[J]. J Funct Foods,2015,15:408-417.
[36].Koeth RA,Wang Z,Levison BS,et al. Intestinal microbiota metabolism of L-carnitine,a nutrient in red meat,promotes atherosclerosis[J]. Nat Med,2013,19(5):576-585.
[37].Estruch R,Ros E,Salas-Salvadó J,et al. Primary prevention of cardiovascular disease with a Mediterranean diet[J]. N Engl J Med,2013,368(14):1279-1290.
[38].Barrea L,Annunziata G,Muscogiuri G, et al. Trimethylamine N-oxide,Mediterranean diet,and nutrition in healthy,normal-weight adults:also a matter of sex?[J]. Nutrition,2019,62:7-17.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(6):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(6):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(6):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(6):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
[11]赵海燕 关秀茹.NLRP3炎症小体介导氧化三甲胺加速动脉粥样硬化的新进展[J].心血管病学进展,2023,(11):1028.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023.11. 000]
ZHAO Haiyan,GUAN Xiuru.NLRP3 Inflammasome in Mediating Trimethylamine?Oxide Accelerates Atherosclerosis[J].Advances in Cardiovascular Diseases,2023,(6):1028.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023.11. 000]